Evidence map›Paper›PMID 38028479›Full record

ReviewFrontiers in cardiovascular medicine2023

Heart graft preservation technics and limits: an update and perspectives.

Aurore Ughetto, François Roubille, Adrien Molina, Pascal Battistella, Philippe Gaudard, Roland Demaria, Julien Guihaire, Alain Lacampagne, Clément Delmas

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. New Perfusion and Preservation Strategies for Donor Hearts.European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Aurore UghettoPhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
François RoubillePhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
Adrien MolinaPhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
Pascal BattistellaCardio-thoracic and Vascular Surgery Department, CHU de Montpellier, University of Montpellier, Montpellier, France.
Philippe GaudardPhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
Roland DemariaCardio-thoracic and Vascular Surgery Department, CHU de Montpellier, University of Montpellier, Montpellier, France.
Julien GuihaireCardiac and Vascular Surgery, Marie Lanelongue Hospital, Paris Saclay University, Le Plessis Robinson, France.
Alain LacampagnePhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
Clément DelmasPhymedexp INSERM, CNRS, University of Montpellier, CHRU Montpellier, Montpellier, France.
Université de Montpellier · FRCentre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Montpellier · FRHôpital Arnaud de Villeneuve · FRHôpital Marie Lannelongue · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart transplantation, the gold standard treatment for end-stage heart failure, is limited by heart graft shortage, justifying expansion of the donor pool. Currently, static cold storage (SCS) of hearts from donations after brainstem death remains the standard practice, but it is usually limited to 240 min. Prolonged cold ischemia and ischemia-reperfusion injury (IRI) have been recognized as major causes of post-transplant graft failure. Continuous ex situ perfusion is a new approach for donor organ management to expand the donor pool and/or increase the utilization rate. Continuous ex situ machine perfusion (MP) can satisfy the metabolic needs of the myocardium, minimizing irreversible ischemic cell damage and cell death. Several hypothermic or normothermic MP methods have been developed and studied, particularly in the preclinical setting, but whether MP is superior to SCS remains controversial. Other approaches seem to be interesting for extending the pool of heart graft donors, such as blocking the paths of apoptosis and necrosis, extracellular vesicle therapy, or donor heart-specific gene therapy. In this systematic review, we summarize the mechanisms involved in IRI during heart transplantation and existing targeting therapies. We also critically evaluate all available data on continuous ex situ perfusion devices for adult donor hearts, highlighting its therapeutic potential and current limitations and shortcomings.

Indexed as

ESNP ex situ normothermic perfusionheart preservationheart tranplantationhypothermic machine perfusion (HMP)MP machine perfusionPGF primary graft failure

Identifiers

PMID38028479
PMCPMC10657826
OpenAlexW4388414151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.